Investigational drug · Phase 3
ASP2138
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "ASP2138"
First trial start
2026
Jul 28, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ASP2138", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastric Adenocarcinoma
- Gastroesophageal Junction (GEJ) Adenocarcinoma
Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ASP2138" as an intervention, largest first.
- A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric CancerPivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07673887 · 570 participants (planned) · Start Jul 28, 2026 · Primary completion Feb 28, 2031
Drug: ASP2138; Pembrolizumab and 6 more · For: Gastric Adenocarcinoma; Gastroesophageal Junction (GEJ) Adenocarcinoma
Sites: Saint Louis Park, Minnesota; Guangzhou, China; Kashiwa, Japan · 12 sites in all
- A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic CancerPivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT05365581 · 398 participants (planned) · Start Jun 7, 2022 · Primary completion May 31, 2028
Drug: ASP2138; Pembrolizumab and 7 more · For: Gastric Adenocarcinoma; Gastroesophageal Junction (GEJ) Adenocarcinoma; Pancreatic Adenocarcinoma
Sites: Orange, California; Santa Monica, California; Chicago, Illinois · 46 sites in all
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07024615 · 25 participants (planned) · Start Oct 16, 2025 · Primary completion Jan 31, 2028
Drug: ASP2138; Oxaliplatin and 6 more · For: Pancreatic Ductal Adenocarcinoma
Sites: Boston, Massachusetts; New York, New York; Durham, North Carolina
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Gastric Adenocarcinoma
- QLS31905Phase 35 trials
Qilu Pharmaceutical Co., Ltd. · Advanced Solid Tumor, CLDN18.2-positive Advanced Biliary Tract Cancer, Gastric Adenocarcinoma
- ASKB589Phase 33 trials
AskGene Pharma, Inc. · Gastric Cancer, Gastroesophageal Cancer (GC), Malignant Solid Tumor
- DenikitugGS-1811, DENPhase 22 trials
Gilead Sciences · Advanced Microsatellite Stable Colorectal Cancer, HER2-negative, Gastroesophageal Junction
- TRK-950Phase 22 trials
Toray Industries, Inc · Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- BHB810Phase 21 trial
BigHat Biosciences, Inc. · Gastric Cancer, Gastric Adenocarcinoma, Gastric (Stomach) Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Astellas.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.